Differentiation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors by their relative lipophilicity

Pharmacy and Pharmacology Communications

Volumn 5, Issue 4, 1999, Pages 269-271

  Joshi, Hemant N ^a   Fakes, Michael G ^a   Serajuddin, A T M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; OCTANOL; PRAVASTATIN; SIMVASTATIN; STATIN; WATER;

ARTICLE; CONTROLLED STUDY; HYDROPHILICITY; LIPOPHILICITY; PARTITION COEFFICIENT; PH;

EID: 0033057651     PISSN: 14608081     EISSN: None     Source Type: Journal    
DOI: 10.1211/146080899128734820     Document Type: Article

References (18)

1. de Vries, A. C. J., Cohen, L. H. (1993) Different effects of hypolipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim. Biophys. Acta 1167: 63-69
2. 12 striated muscle cells to lovastatin and pravastatin. J. Mol. Cell. Cardiol. 27: 2397-2402
3. Guillot, F., Misslin, P., Lamaire, M. (1993) Comparison of fluvastatin and lovastatin blood-barrier transfer using in vitro and in vivo methods. J. Cardiovasc. Pharmacol. 21: 339-346
4. Hamelin, B. A., Turgeon, J. (1998) Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19: 26-37
5. Lennernás, H., Fager, G. (1997) Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: similarities and differences. Clin. Pharmacokinet. 32: 403-425
6. Malinowski, J. M. (1998) Atorvastatin: a hydroxymethylglutaryl-coenzyme A reductase inhibitor. Am. J. Health Syst. Pharm. 55: 2253-2267
7. Mosley, S. T., Kalinowski, S. S., Schafer, B. L., Tanaka, R. D. (1989) Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis. J. Lipid Res. 30: 1411-1420
8. Otto, C., Schwandt, P. (1998) Gibt es Unterschiede zwischen verschiedenen Statinen? Internist 39: 987-993
9. Reijneveld, J. C., Koot, R. W., Bredman, J. J., Joles, J. A., Bár, P. R. (1996) Differential effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the development of myopathy in young rats. Pediatr. Res. 39: 1028-1035
10. Roth, B. D. (1996) The impact of tissue selectivity on the anti-atherosclerotic activity of HMG-CoA reductase inhibitors. Curr. Pharm. Des. 2: 139-154
11. Roth, B. D., Bocan, T. M. A., Blankley, C. J., Chucholowski, A. W., Creger, P. L., Creswell, M. W., Ferguson, E., Newton, R. S., O'Brien, P, Picard, J. A., Roark, W. H., Sekerke, C. S., Sliskovic, D. R., Wilson, M. W. (1991) Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J. Med. Chem. 34: 463-466
12. Roth, T., Richardson, G. R., Sullivan, J. P., Lee, R. M., Merlotti, L., Roehrs, T. (1992) Comparative effects of pravastatin and lovastatin in nighttime sleep and daytime performance. Clin. Cardiol. 15: 426-432
13. Saheki, A., Terasaki, T., Tamai, I., Tsuji, A. (1994) In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm. Res. 11: 305-311
14. Serajuddin, A. T. M., Ranadive, S. A., Mahoney, E. M. (1991) Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, pravastatin, lovastatin, mevastatin, and simvastatin. J. Pharm. Sci. 80: 830-834
15. Sirtori, C. R. (1993) Tissue selectivity of hydroxymethylglutaryl coenzyme A (HMG CoA) reductase inhibitors. Pharmacol. Ther. 60: 431-459
16. van Vliet, A. K., van Thiel, G. C. F., Huisman, R. H., Moshage, H., Yap, S. H., Cohen, L. H. (1995) Different effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on sterol synthesis in various human cell types. Biochim. Biophys. Acta 1254: 105-111
17. +-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am. J. Physiol. 246: G36-G44
18. Yamazaki, Y., Kobayashi, K., Sugiyama, Y. (1996) Primary active transport of pravastatin across the liver canalicular membrane in normal and mutant Eisai hyperbilirubinemic rats. Biopharm. Drug Dispos. 17: 607-62